Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

Annals of Neurology

Volumn 41, Issue 1, 1997, Pages 58-64

  Francois, J G ^a   Vingerhoets, ^a   Schulzer, Michael ^a   Calne, Donald B ^a   Snow, Barry J ^a,b  

^a TRIUMF   (Canada)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; FLUORINE 18;

ADULT; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; DISABILITY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MALE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; RIGIDITY; SYMPTOMATOLOGY; TREMOR;

AGED; CORPUS STRIATUM; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1842290405     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410410111     Document Type: Article

References (48)

1. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Lieberman A, eds. Recenr developments in Parkinson's disease, vol II. Florham Park, NJ: Macmillan Health Care Information, 1987:153-163
2. Duvoisin RC. The evaluation of extrapyramidal disease. In: de Ajuriaguerra J, Gauthier G, eds. Monoamines noyaux gris centraux et syndrome de Parkinson. Geneva: Georg and Cie SA, 1971:313-325
3. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-672
4. The Parkinson Study Group. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183
5. Schulzer M, Mak E, Calne DB. The anti-Parkinson efficacy of deprenyl derives from transient improvement which is likely to be symptomatic. Ann Neurol 1993;32:795-798
6. 18F]Fluorodopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine. Proc Natl Acad Sci USA 1978;75:464-467
7. 18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986;20:258-262
8. 18F]Fluorodopa: a unique gamma emitting substrate for dopa decarboxylase. Experientia 1975;31:1254-1255
9. Garnett ES, Firnau G, Nahmias C. Dopamine visualised in the basal ganglia of living man. Nature 1983;305:137-138
10. Firnau G, Garnett ES, Chan PKH, Belbeck LW. Intracerebral dopamine metabolism studied by novel radioisotope technique. J Pharm Pharmacol 1976;28:584-585
11. Garnett ES, Firnau G, Nahmias C, Chirakal R. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res 1983;280:169-171
12. 18F]fluorodopa uptake, postmortem dopaminergic cell counts and striaral dopaminergic levels. Ann Neurol 1993;34:324-330
13. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP-monkey with dopaminergic indices. Ann Neurol 1993;34:331-338
14. Langston JW, Widner H, Goetz CG, et al. Core Assessment Program for Intracerebral Transplantation (CAPIT). Mov Disord 1992;7:2-13
15. Vingerhoets FJG, Snow BJ, Schulzer M, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 1994;35:18-23
16. Vingerhoets FJG, Snow BJ, Lee CS, et al. Longitudinal fluorodopa positron emission tomography studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-764
17. Leenders KL, Salmon EP, Tyrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298
18. 18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-213
19. 18F]-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-555
20. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32:S125-S127
21. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;5:427-442
22. Hietanen M, Teravainen H, Tsui JK, et al. The pegboard as a measurement of parkinsonian deficit. Neurology 1987;37(suppl 1):266 (Abstract)
23. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989;26:535-542
24. 18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Acta Neurol Scand 1990;81:24-30
25. Brooks DJ, Salmon E, Mathias CJ. The relationship between locomotor disability, autonomie dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure and Parkinson's disease studied with PET. Brain 1990;113:1539-1552
26. Vingerhoets FJG, Schulzer M, Snow BJ. Reproducibility of the fluorodopa positron tomography indices in Parkinson's disease. Mov Disord 1994:9(suppl 1):119
27. 18F]-6-fluorodopa PET correlations in Parkinson's disease: a comparison of 5 methods of PET analysis. J Cereb Blood Flow Metab 1995 (in press) (Abstract)
28. Steiger JH. Tests for comparing elements of a correlation matrix. Psychol Bull 1980;87:245-251
29. Lee CS, Schulzer M, Mak EK, et al. Clinical observation on the rate of progression of idiopathic parkinsonism and a mathematical model of pathogenesis. Parr 1. Clinical observations. Brain 1994;117:501-507
30. Bernheimer H, Birkmeyer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20:415-455
31. Rinne JO, Rummukainen J, Paljarvi L, Rinne UK. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26:47-50
32. Rinne UK, Sonninen V. Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease. Neurology 1972;22:62-67
33. Playford ED, Jenkins IH, Passingham RE, et al. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Adv Neurol 1993;60:506-510
34. Jenkins IH, Fernandez W, Playford ED, et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 1992;32:749-757
35. Dick JPR, Rothwell JC, Day BL, et al. The bereitschaftspotential is abnormal in Parkinson's disease. Brain 1989;112:233-244
36. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism, J Cereb Blood Flow Metab 1994;14:783-801
37. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-271
38. Martinez-Martin P, Gil-Nagel A, Morlan Garcia L, et al. Unified Parkinson's Disease Rating Scale characteristics and structure. Mov Disord 1994;9:76-83
39. Baas H, Stecker K, Fischer PA. Value and appropriate use of rating scales and comparative measurements in quantification of disability in Parkinson's disease. J Neural Transm 1993;5:45-61
40. Delwaide PJ, Gonce M. Pathophysiology of Parkinson's signs. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins, 1993:77-92
41. Marsden CD. Which motor disorder in Parkinson's disease indicates the true motor function of the basal ganglia? Ciba Found Symp 1984;107:225-237
42. Montgomery GK, Reynolds C, Warren RM. Qualitative assessment of Parkinson's disease: study of reliability and data reduction with an abbreviated Columbia scale. Clin Neuropharmacol 1985;8:83-92
43. Geminiani G, Cesana BM, Tamma F, et al. Interobserver reliability between neurologists training in Parkinson's disease rating scales - a multicenter study. Mov Disord 1991;6:330-335
44. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord 1994;9:89-91
45. Lawrence DG, Kuyper HGJM. The functional organization of the motor system in the monkey. I. The effects of bilateral pyramidal lesions. Brain 1968;91:1-14
46. Lawrence DG, Kuyper HGJM. The functional organization of the motor system in the monkey. II. The effects of lesions of the descending brainstem pathways. Brain 1968;91:15-33
47. Gumming P, Kuwabara H, Ase A, et al. Regulation of dopa decarboxylase activity in brain of living rat. J Neurochem 1995;65:1381-1390
48. Schulzer M, Lee CS, Mak EK, et al. Clinical observations on the rate of progression of idiopathic parkinsonism and a mathematical model of pathogenesis. Part II. A mathematical model. Brain 1994;117:509-516